METHOD FOR TREATING RHEUMATOID ARTHRITIS
A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MlF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 26. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SILVER MICHAEL E [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-12-21, Last updated: 2023-12-29 |
|---|
| Patentnummer: |
US2023338324 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA01842287X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA01842287X | ||
| 003 | DE-627 | ||
| 005 | 20231229105915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231110s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA01842287X | ||
| 035 | |a (EPA)US2023338324 | ||
| 035 | |a (EPA)63849959 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SILVER MICHAEL E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METHOD FOR TREATING RHEUMATOID ARTHRITIS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-12-21, Last updated: 2023-12-29 | ||
| 520 | |a A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MlF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 26. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:26 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/63849959/publication/US2023338324A1?q=US2023338324 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 26 |c 10 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 26 |c 10 | ||